AM-Pharma B.V. Gains Fast Track Status for AKI Drug

The FDA has awarded fast track status to AM-Pharma’s intravenous recombinant human alkaline phosphatase to treat acute kidney injury.

The candidate is being investigated in a Phase 2 trial in the U.S. and Europe to evaluate its effect on sepsis-associated AKI.